[Gemcitabine and urogenital tumors].
Among genito-urinary tumors, gemcitabine has only got the marketing approval for advanced urothelial cancer. The combination of gemcitabine and cisplatin has been shown to be a new standard of treatment in this disease because of equal efficacy and lesser toxicity as compared to the classic M-VAC protocol which includes methotrexate, vinblastin, doxorubicin and cisplatin. However new trials are required with the aim of improving survival, especially in the adjuvant setting after cystectomy. The role of gemcitabine in other tumors of the genito-urinary tract has to be determined.
Culine
Stéphane
S
CRLC Val-d'Aurelle, parc Euromédecine, 34298 Montpellier. stculine@valdorel.fnclcc.fr
D000230:Adenocarcinoma / Q000188:drug therapy; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D015653:Cystectomy; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D018237:Germinoma / Q000188:drug therapy; D006402:Hematologic Diseases / Q000139:chemically induced; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage / Q000009:adverse effects; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D018579:Patient Selection; D011471:Prostatic Neoplasms / Q000188:drug therapy; D016879:Salvage Therapy; D016896:Treatment Outcome; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy / Q000601:surgery; D014565:Urogenital Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D009944:Organoplatinum Compounds; D003841:Deoxycytidine; D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate; D000093542:Gemcitabine